|
1.
|
|
11 p, 1.2 MB |
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
/
Madariaga, Ainhoa (Universitat Autònoma de Barcelona) ;
Garg, Swati (University Health Network, Toronto, Canada) ;
Tchrakian, Nairi (University Health Network, Toronto, Canada) ;
Dhani, Neesha C. (University of Toronto, Canada) ;
Jimenez, Waldo (Juravinski Cancer Centre, Hamilton, Canada) ;
Welch, Stephen (London Health Sciences Center, London, Canada) ;
MacKay, Helen (Odette Cancer Centre. Sunnybrook Health Sciences Centre, Toronto, Canada) ;
Ethier, Josee-Lyne (Kingston Health Sciences Cancer Centre, Kingston, Canada) ;
Gilbert, Lucy (Royal Victoria Hospital, Montréal, Canada) ;
Li, Xuan (University Health Network, Toronto, Canada) ;
Rodriguez, Angela (University Health Network, Toronto, Canada) ;
Chan, Lucy (University Health Network, Toronto, Canada) ;
Bowering, Valerie (University Health Network, Toronto, Canada) ;
Clarke, Blaise (University Health Network, Toronto, Canada) ;
Zhang, Tong (University of Toronto, Canada) ;
King, Ian (University of Toronto, Canada) ;
Downs, Gregory (University of Toronto, Canada) ;
Stockley, Tracy (University of Toronto, Canada) ;
Wang, Lisa (University of Toronto, Toronto, Canada) ;
Udagani, Smitha (University Health Network, Toronto, Canada) ;
Oza, Amit M. (University of Toronto, Canada) ;
Lheureux, Stephanie (University of Toronto, Canada)
This multi-centre, non-randomized, open-label, phase II trial (NCT03016338), assessed niraparib monotherapy (cohort 1, C1), or niraparib and dostarlimab (cohort 2, C2) in patients with recurrent serous or endometrioid endometrial carcinoma. [...]
2023 -  10.1038/s41467-023-37084-w
Nature communications, Vol. 14 (2023) , art. 1452
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
